
Although its prevalence in the United States has declined from a peak in the late 1990s (Open Forum Infect Dis 2019;6[suppl 1]:S34-S46), treatment of Acinetobacter baumannii remains challenging for U.S. hospitals, an infectious disease expert noted during the MAD-ID 2023 (Making a Difference in Infectious Diseases) meeting, in Orlando, Fla.
This infection is resistant to nearly all antibiotic classes including fluoroquinolones, aminoglycosides, cephalosporins and carbapenems, said